Pitney Pharmaceuticals

Pitney Pharmaceuticals is an Australian biotechnology company that operates as a subsidiary of Noxopharm. The company is primarily focused on the development of idronoxil, a small molecule drug candidate branded as Veyonda. Veyonda is designed to function as a radio-sensitizer and chemo-sensitizer, enhancing the effectiveness of standard cancer treatments by inhibiting sphingosine kinase and modulating the S1P pathway. Pitney's research aims to address treatment resistance in late-stage cancers, including prostate cancer and soft tissue sarcoma. Additionally, the company explores the use of its technology to manage hyper-inflammatory conditions such as cytokine release syndrome.